text:
Asthma

Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. These may occur a few times a day or a few times per week. Depending on the person, asthma symptoms may become worse at night or with exercise.

Asthma is thought to be caused by a combination of genetic and environmental factors. Environmental factors include exposure to air pollution and allergens. Other potential triggers include medications such as aspirin and beta blockers. Diagnosis is usually based on the pattern of symptoms, response to therapy over time, and spirometry lung function testing. Asthma is classified according to the frequency of symptoms, forced expiratory volume in one second (FEV1), and peak expiratory flow rate. It may also be classified as atopic or non-atopic, where atopy refers to a predisposition toward developing a type 1 hypersensitivity reaction.

There is no known cure for asthma, but it can be controlled. Symptoms can be prevented by avoiding triggers, such as allergens and respiratory irritants, and suppressed with the use of inhaled corticosteroids. Long-acting beta agonists (LABA) or antileukotriene agents may be used in addition to inhaled corticosteroids if asthma symptoms remain uncontrolled. Treatment of rapidly worsening symptoms is usually with an inhaled short-acting beta2 agonist such as salbutamol and corticosteroids taken by mouth. In very severe cases, intravenous corticosteroids, magnesium sulfate, and hospitalization may be required.

In 2019 asthma affected approximately 262 million people and caused approximately 461,000 deaths. Most of the deaths occurred in the developing world. Asthma often begins in childhood, and the rates have increased significantly since the 1960s. Asthma was recognized as early as Ancient Egypt. The word asthma is from the Greek ἆσθμα, âsthma, which means 'panting'.

Signs and symptoms
Asthma is characterized by recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing. Sputum may be produced from the lung by coughing but is often hard to bring up. During recovery from an asthma attack (exacerbation), it may appear pus-like due to high levels of white blood cells called eosinophils. Symptoms are usually worse at night and in the early morning or in response to exercise or cold air. Some people with asthma rarely experience symptoms, usually in response to triggers, whereas others may react frequently and readily and experience persistent symptoms.

Associated conditions
A number of other health conditions occur more frequently in people with asthma, including gastroesophageal reflux disease (GERD), rhinosinusitis, and obstructive sleep apnea. Psychological disorders are also more common, with anxiety disorders occurring in between 16 and 52% and mood disorders in 14–41%. It is not known whether asthma causes psychological problems or psychological problems lead to asthma. Current asthma, but not former asthma, is associated with increased all-cause mortality, heart disease mortality, and chronic lower respiratory tract disease mortality. Asthma, particularly severe asthma, is strongly associated with development of chronic obstructive pulmonary disease (COPD). Those with asthma, especially if it is poorly controlled, are at increased risk for radiocontrast reactions.

Cavities occur more often in people with asthma. This may be related to the effect of beta2-adrenergic agonists decreasing saliva. These medications may also increase the risk of dental erosions.

Causes
Asthma is caused by a combination of complex and incompletely understood environmental and genetic interactions. These influence both its severity and its responsiveness to treatment. It is believed that the recent increased rates of asthma are due to changing epigenetics (heritable factors other than those related to the DNA sequence) and a changing living environment. Asthma that starts before the age of 12 years old is more likely due to genetic influence, while onset after age 12 is more likely due to environmental influence.

Environmental
Many environmental factors have been associated with asthma's development and exacerbation, including allergens, air pollution, and other environmental chemicals. There are some substances that are known to cause asthma in exposed people and they are called asthmagens. Some common asthmagens include ammonia, latex, pesticides, solder and welding fumes, metal or wood dusts, spraying of isocyanate paint in vehicle repair, formaldehyde, glutaraldehyde, anhydrides, glues, dyes, metal working fluids, oil mists, molds. Smoking during pregnancy and after delivery is associated with a greater risk of asthma-like symptoms. Low air quality from environmental factors such as traffic pollution or high ozone levels has been associated with both asthma development and increased asthma severity. Over half of cases in children in the United States occur in areas when air quality is below the EPA standards. Low air quality is more common in low-income and minority communities.

Exposure to indoor volatile organic compounds may be a trigger for asthma; formaldehyde exposure, for example, has a positive association. Phthalates in certain types of PVC are associated with asthma in both children and adults. While exposure to pesticides is linked to the development of asthma, a cause and effect relationship has yet to be established. A meta-analysis concluded gas stoves are a major risk factor for asthma, finding around one in eight cases in the U.S. could be attributed to these.

The majority of the evidence does not support a causal role between paracetamol (acetaminophen) or antibiotic use and asthma. A 2014 systematic review found that the association between paracetamol use and asthma disappeared when respiratory infections were taken into account. Maternal psychological stress during pregnancy is a risk factor for the child to develop asthma.

Asthma is associated with exposure to indoor allergens. Common indoor allergens include dust mites, cockroaches, animal dander (fragments of fur or feathers), and mold. Efforts to decrease dust mites have been found to be ineffective on symptoms in sensitized subjects. Weak evidence suggests that efforts to decrease mold by repairing buildings may help improve asthma symptoms in adults. Certain viral respiratory infections, such as respiratory syncytial virus and rhinovirus, may increase the risk of developing asthma when acquired as young children. Certain other infections, however, may decrease the risk.

Hygiene hypothesis
The hygiene hypothesis attempts to explain the increased rates of asthma worldwide as a direct and unintended result of reduced exposure, during childhood, to non-pathogenic bacteria and viruses. It has been proposed that the reduced exposure to bacteria and viruses is due, in part, to increased cleanliness and decreased family size in modern societies. Exposure to bacterial endotoxin in early childhood may prevent the development of asthma, but exposure at an older age may provoke bronchoconstriction. Evidence supporting the hygiene hypothesis includes lower rates of asthma on farms and in households with pets.

Use of antibiotics in early life has been linked to the development of asthma. Also, delivery via caesarean section is associated with an increased risk (estimated at 20–80%) of asthma – this increased risk is attributed to the lack of healthy bacterial colonization that the newborn would have acquired from passage through the birth canal. There is a link between asthma and the degree of affluence which may be related to the hygiene hypothesis as less affluent individuals often have more exposure to bacteria and viruses.

Genetic
Family history is a risk factor for asthma, with many different genes being implicated. If one identical twin is affected, the probability of the other having the disease is approximately 25%. By the end of 2005, 25 genes had been associated with asthma in six or more separate populations, including GSTM1, IL10, CTLA-4, SPINK5, LTC4S, IL4R and ADAM33, among others. Many of these genes are related to the immune system or modulating inflammation. Even among this list of genes supported by highly replicated studies, results have not been consistent among all populations tested. In 2006 over 100 genes were associated with asthma in one genetic association study alone; more continue to be found.

Some genetic variants may only cause asthma when they are combined with specific environmental exposures. An example is a specific single nucleotide polymorphism in the CD14 region and exposure to endotoxin (a bacterial product). Endotoxin exposure can come from several environmental sources including tobacco smoke, dogs, and farms. Risk for asthma, then, is determined by both a person's genetics and the level of endotoxin exposure.

Medical conditions
A triad of atopic eczema, allergic rhinitis and asthma is called atopy. The strongest risk factor for developing asthma is a history of atopic disease; with asthma occurring at a much greater rate in those who have either eczema or hay fever. Asthma has been associated with eosinophilic granulomatosis with polyangiitis (formerly known as Churg–Strauss syndrome), an autoimmune disease and vasculitis. Individuals with certain types of urticaria may also experience symptoms of asthma.

There is a correlation between obesity and the risk of asthma with both having increased in recent years. Several factors may be at play including decreased respiratory function due to a buildup of fat and the fact that adipose tissue leads to a pro-inflammatory state.

Beta blocker medications such as propranolol can trigger asthma in those who are susceptible. Cardioselective beta-blockers, however, appear safe in those with mild or moderate disease. Other medications that can cause problems in asthmatics are angiotensin-converting enzyme inhibitors, aspirin, and NSAIDs. Use of acid suppressing medication (proton pump inhibitors and H2 blockers) during pregnancy is associated with an increased risk of asthma in the child.

Exacerbation
Some individuals will have stable asthma for weeks or months and then suddenly develop an episode of acute asthma. Different individuals react to various factors in different ways. Most individuals can develop severe exacerbation from a number of triggering agents.

Home factors that can lead to exacerbation of asthma include dust, animal dander (especially cat and dog hair), cockroach allergens and mold. Perfumes are a common cause of acute attacks in women and children. Both viral and bacterial infections of the upper respiratory tract can worsen the disease. Psychological stress may worsen symptoms – it is thought that stress alters the immune system and thus increases the airway inflammatory response to allergens and irritants.

Asthma exacerbations in school‐aged children peak in autumn, shortly after children return to school. This might reflect a combination of factors, including poor treatment adherence, increased allergen and viral exposure, and altered immune tolerance. There is limited evidence to guide possible approaches to reducing autumn exacerbations, but while costly, seasonal omalizumab treatment from four to six weeks before school return may reduce autumn asthma exacerbations.

Pathophysiology
Asthma is the result of chronic inflammation of the conducting zone of the airways (most especially the bronchi and bronchioles), which subsequently results in increased contractability of the surrounding smooth muscles. This among other factors leads to bouts of narrowing of the airway and the classic symptoms of wheezing. The narrowing is typically reversible with or without treatment. Occasionally the airways themselves change. Typical changes in the airways include an increase in eosinophils and thickening of the lamina reticularis. Chronically the airways' smooth muscle may increase in size along with an increase in the numbers of mucous glands. Other cell types involved include T lymphocytes, macrophages, and neutrophils. There may also be involvement of other components of the immune system, including cytokines, chemokines, histamine, and leukotrienes among others.

Diagnosis
While asthma is a well-recognized condition, there is not one universal agreed upon definition. It is defined by the Global Initiative for Asthma as "a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyper-responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction within the lung that is often reversible either spontaneously or with treatment".

There is currently no precise test for the diagnosis, which is typically based on the pattern of symptoms and response to therapy over time. Asthma may be suspected if there is a history of recurrent wheezing, coughing or difficulty breathing and these symptoms occur or worsen due to exercise, viral infections, allergens or air pollution. Spirometry is then used to confirm the diagnosis. In children under the age of six the diagnosis is more difficult as they are too young for spirometry.

Spirometry
Spirometry is recommended to aid in diagnosis and management. It is the single best test for asthma. If the FEV1 measured by this technique improves more than 12% and increases by at least 200 milliliters following administration of a bronchodilator such as salbutamol, this is supportive of the diagnosis. It however may be normal in those with a history of mild asthma, not currently acting up. As caffeine is a bronchodilator in people with asthma, the use of caffeine before a lung function test may interfere with the results. Single-breath diffusing capacity can help differentiate asthma from COPD. It is reasonable to perform spirometry every one or two years to follow how well a person's asthma is controlled.

Others
The methacholine challenge involves the inhalation of increasing concentrations of a substance that causes airway narrowing in those predisposed. If negative it means that a person does not have asthma; if positive, however, it is not specific for the disease.

Other supportive evidence includes: a ≥20% difference in peak expiratory flow rate on at least three days in a week for at least two weeks, a ≥20% improvement of peak flow following treatment with either salbutamol, inhaled corticosteroids or prednisone, or a ≥20% decrease in peak flow following exposure to a trigger. Testing peak expiratory flow is more variable than spirometry, however, and thus not recommended for routine diagnosis. It may be useful for daily self-monitoring in those with moderate to severe disease and for checking the effectiveness of new medications. It may also be helpful in guiding treatment in those with acute exacerbations.

Classification
Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in one second (FEV1), and peak expiratory flow rate. Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic), based on whether symptoms are precipitated by allergens (atopic) or not (non-atopic). While asthma is classified based on severity, at the moment there is no clear method for classifying different subgroups of asthma beyond this system. Finding ways to identify subgroups that respond well to different types of treatments is a current critical goal of asthma research. Recently, asthma has been classified based on whether it is associated with type 2 or non–type 2 inflammation. This approach to immunologic classification is driven by a developing understanding of the underlying immune processes and by the development of therapeutic approaches that target type 2 inflammation.

Although asthma is a chronic obstructive condition, it is not considered as a part of chronic obstructive pulmonary disease, as this term refers specifically to combinations of disease that are irreversible such as bronchiectasis and emphysema. Unlike these diseases, the airway obstruction in asthma is usually reversible; however, if left untreated, the chronic inflammation from asthma can lead the lungs to become irreversibly obstructed due to airway remodeling. In contrast to emphysema, asthma affects the bronchi, not the alveoli. The combination of asthma with a component of irreversible airway obstruction has been termed the asthma-chronic obstructive disease (COPD) overlap syndrome (ACOS). Compared to other people with "pure" asthma or COPD, people with ACOS exhibit increased morbidity, mortality and possibly more comorbidities.

Asthma exacerbation
An acute asthma exacerbation is commonly referred to as an asthma attack. The classic symptoms are shortness of breath, wheezing, and chest tightness. The wheezing is most often when breathing out. While these are the primary symptoms of asthma, some people present primarily with coughing, and in severe cases, air motion may be significantly impaired such that no wheezing is heard. In children, chest pain is often present.

Signs occurring during an asthma attack include the use of accessory muscles of respiration (sternocleidomastoid and scalene muscles of the neck), there may be a paradoxical pulse (a pulse that is weaker during inhalation and stronger during exhalation), and over-inflation of the chest. A blue color of the skin and nails may occur from lack of oxygen.

In a mild exacerbation the peak expiratory flow rate (PEFR) is ≥200 L/min, or ≥50% of the predicted best. Moderate is defined as between 80 and 200 L/min, or 25% and 50% of the predicted best, while severe is defined as ≤ 80 L/min, or ≤25% of the predicted best.

Acute severe asthma, previously known as status asthmaticus, is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators and corticosteroids. Half of cases are due to infections with others caused by allergen, air pollution, or insufficient or inappropriate medication use.

Brittle asthma is a kind of asthma distinguishable by recurrent, severe attacks. Type 1 brittle asthma is a disease with wide peak flow variability, despite intense medication. Type 2 brittle asthma is background well-controlled asthma with sudden severe exacerbations.

Exercise-induced
Exercise can trigger bronchoconstriction both in people with or without asthma. It occurs in most people with asthma and up to 20% of people without asthma. Exercise-induced bronchoconstriction is common in professional athletes. The highest rates are among cyclists (up to 45%), swimmers, and cross-country skiers. While it may occur with any weather conditions, it is more common when it is dry and cold. Inhaled beta2 agonists do not appear to improve athletic performance among those without asthma; however, oral doses may improve endurance and strength.

Occupational
Asthma as a result of (or worsened by) workplace exposures is a commonly reported occupational disease. Many cases, however, are not reported or recognized as such. It is estimated that 5–25% of asthma cases in adults are work-related. A few hundred different agents have been implicated, with the most common being isocyanates, grain and wood dust, colophony, soldering flux, latex, animals, and aldehydes. The employment associated with the highest risk of problems include those who spray paint, bakers and those who process food, nurses, chemical workers, those who work with animals, welders, hairdressers and timber workers.

Aspirin-exacerbated respiratory disease
Aspirin-exacerbated respiratory disease (AERD), also known as aspirin-induced asthma, affects up to 9% of asthmatics. AERD consists of asthma, nasal polyps, sinus disease, and respiratory reactions to aspirin and other NSAID medications (such as ibuprofen and naproxen). People often also develop loss of smell and most experience respiratory reactions to alcohol.

Alcohol-induced asthma
Alcohol may worsen asthmatic symptoms in up to a third of people. This may be even more common in some ethnic groups such as the Japanese and those with aspirin-exacerbated respiratory disease. Other studies have found improvement in asthmatic symptoms from alcohol.

Non-atopic asthma
Non-atopic asthma, also known as intrinsic or non-allergic, makes up between 10 and 33% of cases. There is negative skin test to common inhalant allergens. Often it starts later in life, and women are more commonly affected than men. Usual treatments may not work as well. The concept that "non-atopic" is synonymous with "non-allergic" is called into question by epidemiological data that the prevalence of asthma is closely related to the serum IgE level standardized for age and sex (P<0.0001), indicating that asthma is almost always associated with some sort of IgE-related reaction and therefore has an allergic basis, although not all the allergic stimuli that cause asthma appear to have been included in the battery of aeroallergens studied (the "missing antigen(s)" hypothesis). For example, an updated systematic review and meta-analysis of population-attributable risk (PAR) of Chlamydia pneumoniae biomarkers in chronic asthma found that the PAR for C. pneumoniae-specific IgE was 47%.

Infectious asthma
Infectious asthma is an easily identified clinical presentation. When queried, asthma patients may report that their first asthma symptoms began after an acute lower respiratory tract illness. This type of history has been labelled the "infectious asthma" (IA) syndrome, or as "asthma associated with infection" (AAWI) to distinguish infection-associated asthma initiation from the well known association of respiratory infections with asthma exacerbations. Reported clinical prevalences of IA for adults range from around 40% in a primary care practice to 70% in a specialty practice treating mainly severe asthma patients. Additional information on the clinical prevalence of IA in adult-onset asthma is unavailable because clinicians are not trained to elicit this type of history routinely, and recollection in child-onset asthma is challenging. A population-based incident case-control study in a geographically defined area of Finland reported that 35.8% of new-onset asthma cases had experienced acute bronchitis or pneumonia in the year preceding asthma onset, representing a significantly higher risk compared to randomly selected controls (Odds ratio 7.2, 95% confidence interval 5.2-10).

Phenotyping and endotyping
Asthma phenotyping and endotyping has emerged as a novel approach to asthma classification inspired by precision medicine which separates the clinical presentations of asthma, or asthma phenotypes, from their underlying causes, or asthma endotypes. The best-supported endotypic distinction is the type 2-high/type 2-low distinction. Classification based on type 2 inflammation is useful in predicting which patients will benefit from targeted biologic therapy.

Differential diagnosis
Many other conditions can cause symptoms similar to those of asthma. In children, symptoms may be due to other upper airway diseases such as allergic rhinitis and sinusitis, as well as other causes of airway obstruction including foreign body aspiration, tracheal stenosis, laryngotracheomalacia, vascular rings, enlarged lymph nodes or neck masses. Bronchiolitis and other viral infections may also produce wheezing. According to European Respiratory Society, it may not be suitable to label wheezing preschool children with the term "asthma" because there is lack of clinical data on inflammation in airways. In adults, COPD, congestive heart failure, airway masses, as well as drug-induced coughing due to ACE inhibitors may cause similar symptoms. In both populations vocal cord dysfunction may present similarly.

Chronic obstructive pulmonary disease can coexist with asthma and can occur as a complication of chronic asthma. After the age of 65, most people with obstructive airway disease will have asthma and COPD. In this setting, COPD can be differentiated by increased airway neutrophils, abnormally increased wall thickness, and increased smooth muscle in the bronchi. However, this level of investigation is not performed due to COPD and asthma sharing similar principles of management: corticosteroids, long-acting beta-agonists, and smoking cessation. It closely resembles asthma in symptoms, is correlated with more exposure to cigarette smoke, an older age, less symptom reversibility after bronchodilator administration, and decreased likelihood of family history of atopy.

Prevention
The evidence for the effectiveness of measures to prevent the development of asthma is weak. The World Health Organization recommends decreasing risk factors such as tobacco smoke, air pollution, chemical irritants including perfume, and the number of lower respiratory infections. Other efforts that show promise include: limiting smoke exposure in utero, breastfeeding, and increased exposure to daycare or large families, but none are well supported enough to be recommended for this indication.

Early pet exposure may be useful. Results from exposure to pets at other times are inconclusive and it is only recommended that pets be removed from the home if a person has allergic symptoms to said pet.

Dietary restrictions during pregnancy or when breastfeeding have not been found to be effective at preventing asthma in children and are not recommended. Omega-3 consumption, mediterranean diet and anti-oxidants have been suggested by some studies that might help preventing crisis but the evidence is still inconclusive.

Reducing or eliminating compounds known to sensitive people from the work place may be effective. It is not clear if annual influenza vaccinations affects the risk of exacerbations. Immunization, however, is recommended by the World Health Organization. Smoking bans are effective in decreasing exacerbations of asthma.

Management
While there is no cure for asthma, symptoms can typically be improved. The most effective treatment for asthma is identifying triggers, such as cigarette smoke, pets or other allergens, and eliminating exposure to them. If trigger avoidance is insufficient, the use of medication is recommended. Pharmaceutical drugs are selected based on, among other things, the severity of illness and the frequency of symptoms. Specific medications for asthma are broadly classified into fast-acting and long-acting categories. The medications listed below have demonstrated efficacy in improving asthma symptoms; however, real world use-effectiveness is limited as around half of people with asthma worldwide remain sub-optimally controlled, even when treated. People with asthma may remain sub-optimally controlled either because optimum doses of asthma medications do not work (called "refractory" asthma) or because individuals are either unable (e.g. inability to afford treatment, poor inhaler technique) or unwilling (e.g., wish to avoid side effects of corticosteroids) to take optimum doses of prescribed asthma medications (called "difficult to treat" asthma). In practice, it is not possible to distinguish "refractory" from "difficult to treat" categories for patients who have never taken optimum doses of asthma medications. A related issue is that the asthma efficacy trials upon which the pharmacological treatment guidelines are based have systematically excluded the majority of people with asthma. For example, asthma efficacy treatment trials always exclude otherwise eligible people who smoke, and smoking diminishes the efficacy of inhaled corticosteroids, the mainstay of asthma control management.

Bronchodilators are recommended for short-term relief of symptoms. In those with occasional attacks, no other medication is needed. If mild persistent disease is present (more than two attacks a week), low-dose inhaled corticosteroids or alternatively, a leukotriene antagonist or a mast cell stabilizer by mouth is recommended. For those who have daily attacks, a higher dose of inhaled corticosteroids is used. In a moderate or severe exacerbation, corticosteroids by mouth are added to these treatments.

People with asthma have higher rates of anxiety, psychological stress, and depression. This is associated with poorer asthma control. Cognitive behavioral therapy may improve quality of life, asthma control, and anxiety levels in people with asthma.

Improving people's knowledge about asthma and using a written action plan has been identified as an important component of managing asthma. Providing educational sessions that include information specific to a person's culture is likely effective. More research is necessary to determine if increasing preparedness and knowledge of asthma among school staff and families using home-based and school interventions results in long term improvements in safety for children with asthma. School-based asthma self-management interventions, which attempt to improve knowledge of asthma, its triggers and the importance of regular practitioner review, may reduce hospital admissions and emergency department visits. These interventions may also reduce the number of days children experience asthma symptoms and may lead to small improvements in asthma-related quality of life. More research is necessary to determine if shared-decision-making is helpful for managing adults with asthma or if a personalized asthma action plan is effective and necessary. Some people with asthma use pulse oximeters to monitor their own blood oxygen levels during an asthma attack. However, there is no evidence regarding the use in these instances.

Lifestyle modification
Avoidance of triggers is a key component of improving control and preventing attacks. The most common triggers include allergens, smoke (from tobacco or other sources), air pollution, nonselective beta-blockers, and sulfite-containing foods. Cigarette smoking and second-hand smoke (passive smoke) may reduce the effectiveness of medications such as corticosteroids. Laws that limit smoking decrease the number of people hospitalized for asthma. Dust mite control measures, including air filtration, chemicals to kill mites, vacuuming, mattress covers and others methods had no effect on asthma symptoms. There is insufficient evidence to suggest that dehumidifiers are helpful for controlling asthma.

Overall, exercise is beneficial in people with stable asthma. Yoga could provide small improvements in quality of life and symptoms in people with asthma. More research is necessary to determine how effective weight loss is on improving quality of life, the usage of health care services, and adverse effects for people of all ages with asthma.

Medications
Medications used to treat asthma are divided into two general classes: quick-relief medications used to treat acute symptoms; and long-term control medications used to prevent further exacerbation. Antibiotics are generally not needed for sudden worsening of symptoms or for treating asthma at any time.

Medications for asthma exacerbations

 * Short-acting beta2-adrenoceptor agonists (SABA), such as salbutamol (albuterol USAN) are the first line treatment for asthma symptoms. They are recommended before exercise in those with exercise induced symptoms.
 * Anticholinergic medications, such as ipratropium, provide additional benefit when used in combination with SABA in those with moderate or severe symptoms and may prevent hospitalizations. Anticholinergic bronchodilators can also be used if a person cannot tolerate a SABA. If a child requires admission to hospital additional ipratropium does not appear to help over a SABA. For children over 2 years old with acute asthma symptoms, inhaled anticholinergic medications taken alone is safe but is not as effective as inhaled SABA or SABA combined with inhaled anticholinergic medication. Adults who receive combined inhaled medications that includes short-acting anticholinergics and SABA may be at risk for increased adverse effects such as experiencing a tremor, agitation, and heart beat palpitations compared to people who are treated with SABA by itself.
 * Older, less selective adrenergic agonists, such as inhaled epinephrine, have similar efficacy to SABAs. They are however not recommended due to concerns regarding excessive cardiac stimulation.
 * Corticosteroids can also help with the acute phase of an exacerbation because of their antiinflamatory properties. The benefit of systemic and oral corticosteroids is well established. Inhaled or nebulized corticosteroids can also be used. For adults and children who are in the hospital due to acute asthma, systemic (IV) corticosteroids improve symptoms. A short course of corticosteroids after an acute asthma exacerbation may help prevent relapses and reduce hospitalizations.
 * Other remedies, less established, are intravenous or nebulized magnesium sulfate and helium mixed with oxygen. Aminophylline could be used with caution as well.
 * Mechanical ventilation is the last resort in case of severe hypoxemia.
 * Intravenous administration of the drug aminophylline does not provide an improvement in bronchodilation when compared to standard inhaled beta-2 agonist treatment. Aminophylline treatment is associated with more adverse effects compared to inhaled beta-2 agonist treatment.

Long–term control

 * Corticosteroids are generally considered the most effective treatment available for long-term control. Inhaled forms are usually used except in the case of severe persistent disease, in which oral corticosteroids may be needed. Dosage depends on the severity of symptoms. High dosage and long term use might lead to the appearance of common adverse effects which are growth delay, adrenal suppression, and osteoporosis. Continuous (daily) use of an inhaled corticosteroid, rather than its intermitted use, seems to provide better results in controlling asthma exacerbations. Commonly used corticosteroids are  budesonide, fluticasone, mometasone and ciclesonide.
 * Long-acting beta-adrenoceptor agonists (LABA) such as salmeterol and formoterol can improve asthma control, at least in adults, when given in combination with inhaled corticosteroids. In children this benefit is uncertain. When used without steroids they increase the risk of severe side-effects, and with corticosteroids they may slightly increase the risk.  Evidence suggests that for children who have persistent asthma, a treatment regime that includes LABA added to inhaled corticosteroids may improve lung function but does not reduce the amount of serious exacerbations. Children who require LABA as part of their asthma treatment may need to go to the hospital more frequently.
 * Leukotriene receptor antagonists (anti-leukotriene agents such as montelukast and zafirlukast) may be used in addition to inhaled corticosteroids, typically also in conjunction with a LABA.  For adults or adolescents who have persistent asthma that is not controlled very well, the addition of anti-leukotriene agents along with daily inhaled corticosteriods improves lung function and reduces the risk of moderate and severe asthma exacerbations. Anti-leukotriene agents may be effective alone for adolescents and adults; however, there is no clear research suggesting which people with asthma would benefit from anti-leukotriene receptor alone.  In those under five years of age, anti-leukotriene agents were the preferred add-on therapy after inhaled corticosteroids. A 2013 Cochrane systematic review concluded that anti-leukotriene agents appear to be of little benefit when added to inhaled steroids for treating children. A similar class of drugs, 5-LOX inhibitors, may be used as an alternative in the chronic treatment of mild to moderate asthma among older children and adults.  there is one medication in this family known as zileuton.
 * Mast cell stabilizers (such as cromolyn sodium) are safe alternatives to corticosteroids but not preferred because they have to be administered frequently.
 * Oral Theophyllines are sometimes used for controlling chronic asthma, but their used is minimized because of their side effects.
 * Omalizumab, a monoclonal Antibody Against IgE, is a novel way to lessen exacerbations by decreasing the levels of circulating IgE that play a significant role at allergic asthma.
 * Anticholinergic medications such as ipratropium bromide have not been shown to be beneficial for treating chronic asthma in children over 2 years old, but is not suggested for routine treatment of chronic asthma in adults.
 * There is no strong evidence to recommend chloroquine medication as a replacement for taking corticosteroids by mouth (for those who are not able to tolerate inhaled steroids). Methotrexate is not suggested as a replacement for taking corticosteriods by mouth ("steroid sparing") due to the adverse effects associated with taking methotrexate and the minimal relief provided for asthma symptoms.
 * Macrolide antibiotics, particularly the azalide macrolide azithromycin, are a recently added GINA-recommended treatment option for both eosinophilic and non-eosinophilic severe, refractory asthma based on azithromycin's efficacy in reducing moderate and severe exacerbations combined. Azithromycin's mechanism of action is not established, and could involve  pathogen- and/or host-directed anti-inflammatory activities. Limited clinical observations suggest that some patients with new-onset asthma and with "difficult-to-treat" asthma (including those with the asthma-COPD overlap syndrome - ACOS) may respond dramatically to azithromycin. However, these groups of asthma patients have not been studied in randomized treatment trials and patient selection needs to be carefully individualized.

For children with asthma which is well-controlled on combination therapy of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA), the benefits and harms of stopping LABA and stepping down to ICS-only therapy are uncertain. In adults who have stable asthma while they are taking a combination of LABA and inhaled corticosteroids (ICS), stopping LABA may increase the risk of asthma exacerbations that require treatment with corticosteroids by mouth. Stopping LABA probably makes little or no important difference to asthma control or asthma-related quality of life. Whether or not stopping LABA increases the risk of serious adverse events or exacerbations requiring an emergency department visit or hospitalisation is uncertain.

Delivery methods
Medications are typically provided as metered-dose inhalers (MDIs) in combination with an asthma spacer or as a dry powder inhaler. The spacer is a plastic cylinder that mixes the medication with air, making it easier to receive a full dose of the drug. A nebulizer may also be used. Nebulizers and spacers are equally effective in those with mild to moderate symptoms. However, insufficient evidence is available to determine whether a difference exists in those with severe disease. For delivering short-acting beta-agonists in acute asthma in children, spacers may have advantages compared to nebulisers, but children with life-threatening asthma have not been studied. There is no strong evidence for the use of intravenous LABA for adults or children who have acute asthma. There is insufficient evidence to directly compare the effectiveness of a metered-dose inhaler attached to a homemade spacer compared to commercially available spacer for treating children with asthma.

Adverse effects
Long-term use of inhaled corticosteroids at conventional doses carries a minor risk of adverse effects. Risks include thrush, the development of cataracts, and a slightly slowed rate of growth. Rinsing the mouth after the use of inhaled steroids can decrease the risk of thrush. Higher doses of inhaled steroids may result in lower bone mineral density.

Others
Inflammation in the lungs can be estimated by the level of exhaled nitric oxide. The use of exhaled nitric oxide levels (FeNO) to guide asthma medication dosing may have small benefits for preventing asthma attacks but the potential benefits are not strong enough for this approach to be universally recommended as a method to guide asthma therapy in adults or children.

When asthma is unresponsive to usual medications, other options are available for both emergency management and prevention of flareups. Additional options include:
 * Humidified oxygen to alleviate hypoxia if saturations fall below 92%.
 * Corticosteroid by mouth are recommended with five days of prednisone being the same 2 days of dexamethasone. One review recommended a seven-day course of steroids.
 * Magnesium sulfate intravenous treatment increases bronchodilation when used in addition to other treatment in moderate severe acute asthma attacks. In adults intravenous treatment results in a reduction of hospital admissions. Low levels of evidence suggest that inhaled (nebulised) magnesium sulfate may have a small benefit for treating acute asthma in adults. Overall, high quality evidence do not indicate a large benefit for combining magnesium sulfate with standard inhaled treatments for adults with asthma.
 * Heliox, a mixture of helium and oxygen, may also be considered in severe unresponsive cases.
 * Intravenous salbutamol is not supported by available evidence and is thus used only in extreme cases.
 * Methylxanthines (such as theophylline) were once widely used, but do not add significantly to the effects of inhaled beta-agonists. Their use in acute exacerbations is controversial.
 * The dissociative anesthetic ketamine is theoretically useful if intubation and mechanical ventilation is needed in people who are approaching respiratory arrest; however, there is no evidence from clinical trials to support this. A 2012 Cochrane review found no significant benefit from the use of ketamine in severe acute asthma in children.
 * For those with severe persistent asthma not controlled by inhaled corticosteroids and LABAs, bronchial thermoplasty may be an option. It involves the delivery of controlled thermal energy to the airway wall during a series of bronchoscopies. While it may increase exacerbation frequency in the first few months it appears to decrease the subsequent rate. Effects beyond one year are unknown.
 * Monoclonal antibody injections such as mepolizumab, dupilumab, or omalizumab may be useful in those with poorly controlled atopic asthma. However, these medications are expensive and their use is therefore reserved for those with severe symptoms to achieve cost-effectiveness. Monoclonal antibodies targeting interleukin-5 (IL-5) or its receptor (IL-5R), including mepolizumab, reslizumab or benralizumab, in addition to standard care in severe asthma is effective in reducing the rate of asthma exacerbations. There is limited evidence for improved health-related quality of life and lung function.
 * Evidence suggests that sublingual immunotherapy in those with both allergic rhinitis and asthma improve outcomes.
 * It is unclear if non-invasive positive pressure ventilation in children is of use as it has not been sufficiently studied.

Adherence to asthma treatments
Staying with a treatment approach for preventing asthma exacerbations can be challenging, especially if the person is required to take medicine or treatments daily. Reasons for low adherence range from a conscious decision to not follow the suggested medical treatment regime for various reasons including avoiding potential side effects, misinformation, or other beliefs about the medication. Problems accessing the treatment and problems administering the treatment effectively can also result in lower adherence. Various approaches have been undertaken to try and improve adherence to treatments to help people prevent serious asthma exacerbations including digital interventions.

Alternative medicine
Many people with asthma, like those with other chronic disorders, use alternative treatments; surveys show that roughly 50% use some form of unconventional therapy. There is little data to support the effectiveness of most of these therapies.

Evidence is insufficient to support the usage of vitamin C or vitamin E for controlling asthma. There is tentative support for use of vitamin C in exercise induced bronchospasm. Fish oil dietary supplements (marine n-3 fatty acids) and reducing dietary sodium do not appear to help improve asthma control. In people with mild to moderate asthma, treatment with vitamin D supplementation or its hydroxylated metabolites does not reduce acute exacerbations or improve control. There is no strong evidence to suggest that vitamin D supplements improve day-to-day asthma symptoms or a person's lung function. There is no strong evidence to suggest that adults with asthma should avoid foods that contain monosodium glutamate (MSG). There have not been enough high-quality studies performed to determine if children with asthma should avoid eating food that contains MSG.

Acupuncture is not recommended for the treatment as there is insufficient evidence to support its use. Air ionisers show no evidence that they improve asthma symptoms or benefit lung function; this applied equally to positive and negative ion generators. Manual therapies, including osteopathic, chiropractic, physiotherapeutic and respiratory therapeutic maneuvers, have insufficient evidence to support their use in treating asthma. Pulmonary rehabilitation, however, may improve quality of life and functional exercise capacity when compared to usual care for adults with asthma. The Buteyko breathing technique for controlling hyperventilation may result in a reduction in medication use; however, the technique does not have any effect on lung function. Thus an expert panel felt that evidence was insufficient to support its use. There is no clear evidence that breathing exercises are effective for treating children with asthma.

Prognosis
The prognosis for asthma is generally good, especially for children with mild disease. Mortality has decreased over the last few decades due to better recognition and improvement in care. In 2010 the death rate was 170 per million for males and 90 per million for females. Rates vary between countries by 100-fold.

Globally it causes moderate or severe disability in 19.4 million people (16 million of which are in low and middle income countries). Of asthma diagnosed during childhood, half of cases will no longer carry the diagnosis after a decade. Airway remodeling is observed, but it is unknown whether these represent harmful or beneficial changes. More recent data find that severe asthma can result in airway remodeling and the "asthma with chronic obstructive pulmonary disease syndrome (ACOS)" that has a poor prognosis. Early treatment with corticosteroids seems to prevent or ameliorates a decline in lung function. Asthma in children also has negative effects on quality of life of their parents.

Epidemiology
In 2019, approximately 262 million people worldwide were affected by asthma and approximately 461,000 people died from the disease. Rates vary between countries with prevalences between 1 and 18%. It is more common in developed than developing countries. One thus sees lower rates in Asia, Eastern Europe and Africa. Within developed countries it is more common in those who are economically disadvantaged while in contrast in developing countries it is more common in the affluent. The reason for these differences is not well known. Low and middle income countries make up more than 80% of the mortality.

While asthma is twice as common in boys as girls, severe asthma occurs at equal rates. In contrast adult women have a higher rate of asthma than men and it is more common in the young than the old. In 2010, children with asthma experienced over 900,000 emergency department visits, making it the most common reason for admission to the hospital following an emergency department visit in the US in 2011.

Global rates of asthma have increased significantly between the 1960s and 2008 with it being recognized as a major public health problem since the 1970s. Rates of asthma have plateaued in the developed world since the mid-1990s with recent increases primarily in the developing world. Asthma affects approximately 7% of the population of the United States and 5% of people in the United Kingdom. Canada, Australia and New Zealand have rates of about 14–15%.

The average death rate from 2011 to 2015 from asthma in the UK was about 50% higher than the average for the European Union and had increased by about 5% in that time. Children are more likely see a physician due to asthma symptoms after school starts in September.

Population-based epidemiological studies describe temporal associations between acute respiratory illnesses, asthma, and development of severe asthma with irreversible airflow limitation (known as the asthma-chronic obstructive pulmonary disease "overlap" syndrome, or ACOS). Additional prospective population-based data indicate that ACOS seems to represent a form of severe asthma, characterised by more frequent hospitalisations, and to be the result of early-onset asthma that has progressed to fixed airflow obstruction.

Economics
From 2000 to 2010, the average cost per asthma-related hospital stay in the United States for children remained relatively stable at about $3,600, whereas the average cost per asthma-related hospital stay for adults increased from $5,200 to $6,600. In 2010, Medicaid was the most frequent primary payer among children and adults aged 18–44 years in the United States; private insurance was the second most frequent payer. Among both children and adults in the lowest income communities in the United States there is a higher rate of hospital stays for asthma in 2010 than those in the highest income communities.

History
Asthma was recognized in ancient Egypt and was treated by drinking an incense mixture known as kyphi. It was officially named as a specific respiratory problem by Hippocrates circa 450 BC, with the Greek word for "panting" forming the basis of our modern name. In 200 BC it was believed to be at least partly related to the emotions. In the 12th century the Jewish physician-philosopher Maimonides wrote a treatise on asthma in Arabic, based partly on Arabic sources, in which he discussed the symptoms, proposed various dietary and other means of treatment, and emphasized the importance of climate and clean air. Chinese Traditional Medicine also offered medication for asthma, as indicated by a surviving 14th century manuscript curated by the Wellcome Foundation.

In 1873, one of the first papers in modern medicine on the subject tried to explain the pathophysiology of the disease while one in 1872, concluded that asthma can be cured by rubbing the chest with chloroform liniment.

Medical treatment in 1880 included the use of intravenous doses of a drug called pilocarpine.

In 1886, F. H. Bosworth theorized a connection between asthma and hay fever.

At the beginning of the 20th century, the focus was the avoidance of allergens as well as selective beta-2 adrenoceptors agonists were used as treatment strategies.

Epinephrine was first referred to in the treatment of asthma in 1905.

Oral corticosteroids began to be used for this condition in the 1950.

The use of a pressurized metered-dose inhaler in the mid-1950 has been developed for the administration of adrenaline and isoproterenol and was later used as a β2-adrenergic agonist.

Inhaled corticosteroids and selective short acting beta agonist came into wide use in the 1960s.

A well-documented case in the 19th century was that of young Theodore Roosevelt (1858–1919). At that time there was no effective treatment. Roosevelt's youth was in large part shaped by his poor health partly related to his asthma. He experienced recurring nighttime asthma attacks that felt as if he was being smothered to death, terrifying the boy and his parents.

During the 1930s to 1950s, asthma was known as one of the "holy seven" psychosomatic illnesses. Its cause was considered to be psychological, with treatment often based on psychoanalysis and other talking cures. As these psychoanalysts interpreted the asthmatic wheeze as the suppressed cry of the child for its mother, they considered the treatment of depression to be especially important for individuals with asthma.

In January 2021, an appeal court in France overturned a deportation order against a 40-year-old Bangladeshi man, who was a patient of asthma. His lawyers had argued that the dangerous levels of pollution in Bangladesh could possibly lead to worsening of his health condition, or even premature death.

title: Asthma


text:
Talk:Playing card

Bridge/Poker sizes question
Could anyone include something indicating information about common card sizes? You commonly (in english-speaking countries) see cards listed as either bridge or poker size -- what's the difference? Are there any other sizes commonly used, eg I sometimes see decks advertised as pinochle decks. AxS 14:57, 26 July 2007 (UTC)

Concerning the common sizes, I just measured a pack of Bicycle brand poker cards. They are definitely 63 mm by 88 mm. Are we sure the most common size is 62 and not 63 mm? Is it possible the common width has changed over time? --Trakon 09:49, 28 September 2007 (UTC)

 * While I don't know the sizes off the top of my head, "Bridge size" cards are narrower than "poker size." This is probably because you hold 13 cards in bridge, and almost never more than 5 in poker.  Pinochle decks are a 48 card deck with 9 through Ace of each suit, twice.  Schoop (talk) 19:46, 19 November 2008 (UTC)

Related to the sizes, the article states "The most common sizes for playing cards are poker size (2.5×3.5 inches (63.5×88.9 mm), or B8 size according to ISO 216) and bridge size (2.25×3.5 inches (56×87 mm)), the latter being narrower.[25]". The reference only states that the size is 2.3x3.5 inches and says nothing about B8 size. B8 size is not 2.3x3.5 inches, it is 62x88 mm, which is a different size. Which is it? I assume 2.5x3.5 because of the reference, but I can't be sure. Potatoj316 (talk) 20:21, 24 June 2013 (UTC)

Did this information get removed? I'd also like to see information on the overall card shape; I recall learning that the the current rectangular shape is relatively new, and that (for example) circular cards were once popular. Modern Poker-sized playing cards agree with B8 in ISO 216, which surely can't be coincidental, so this seems to suggest that this size can't be older than 1798. Joule36e5 (talk) 07:40, 17 February 2015 (UTC)

 * It was moved to Standard 52-card deck where it fits better. As for shapes, rectangular is older and far more common. The oldest cards from China and the Arabs tend to be thin and long strips, this is still reflected in Italian suited cards. Round cards exist in India (see Ganjifa) but they were converted from rectangular Iranian cards. Rounds decks were also made around 1500 in Germany but they seem to be collector's items and never played with.--Countakeshi (talk) 18:24, 24 May 2015 (UTC)

the argument is finally settled: Name of standard deck
After I noticed the inconsitencies and un-earnt credit in the naming of the standard deck here as the "Anglo-American deck", I did a bit of checking and now we can put this debate to rest. At these seemingly reliable sites, it just calls it the French deck straight up: http://www.answers.com/topic/playing-card http://www.coolquiz.com/trivia/explain/docs/cards.asp http://www.briscolausa.com/howtoplay.htm http://www.gamblerinsight.com/index.php/poker/poker-room-reviews/poker/poker-articles/307-the-four-kings.html http://gamingzion.com/poker/france/ http://boardgamegeek.com/thread/417277/play-lost-cities-with-a-normal-poker-french-card-d Even other wikipedia pages refer to it as the French deck: http://en.wikipedia.org/wiki/Suit_%28cards%29 I was hoping to use the Bicycle website as a source, but I noticed that it translated Baccarat Chemin de Fer by the incorrect urban myth and also kept alive the urban myth that the Viet Cong were terrified of the Ace of Spades.

This site provided the best explanation as to why some people don't call it the French deck: http://www.cardplayer.com/cardplayer-magazines/65790-michael-mizrachi-23-14/articles/19403-court-cards The letters have been translated (from Roi to King for example) and the pictures are in a slightly different style. Still, as many of the previous sources have indicated, those differences are frivolous and just to be expected. The only mention I could find for why America has any claim to the name is because America introduced the Joker in order to play Bridge I think it was. What they failed to point out though is that the original French Tarot deck already had the fool which is depicted in the same way as the Joker and plays the same function as the Joker in Tarot. So it would be more correct to say that the Americans "brought back the joker". It might interest you to know that most people seemed to not even realise that some countries have different decks; merely calling it a "standard deck" or a "52-card deck".

The confusion about the French deck turns out to be harmless, it seems. An American game Telsina strips down the deck and some people seem to nickname this new deck as the "French deck" but I couldn't find any explanation for how this makes it French. http://eupokersite.com/telesina/

So there you have it; we don't need to be confused about the names anymore; it's the "French deck" and has been for centuries. If anyone is keen to improve the sources, looking in Hoyle's book of rules would be a good place to look. I don't have the book myself so I couldn't check.Owen214 (talk) 10:24, 15 November 2010 (UTC)

 * I can answer some of your asked and un-asked questions. "French deck" isn't really better than "Anglo-American deck", because it also refers to a specific style and refers specifically to R for the king, etc. What I normally use instead is "French-suited deck". Although there are also French-suited tarot decks, tarot decks are rare enough overall so that there should be no ambiguity in practice.
 * The tarot deck is not originally French but was invented in Italy and originally had Italian/Spanish suits. The French suits were invented later, and were applied to tarot decks even later. (In France this happened as late as the 19th century, in some other places earlier.)
 * There is a small number of serious researchers on card games and playing cards, such as David Parlett, John McLeod and Michael Dummett. They all agree that in spite of the similar depictions, the Joker is unrelated to the Fool. It was introduced for the game Euchre, which originally was called Jucker (pronounced like "yooker"). The Joker serves as an additional Jack, and the Jacks in that game were also sometimes called Juckers.
 * Although I think we shouldn't follow the practice, calling a "stripped" 32-card deck a "French deck" makes sense in that most modern French card games are played with such decks, in the same way that most modern Spanish card games are played with 40-card decks. In Germany one distinguishes between the (French-suited) "French deck" and the (German-suited) "German deck", both of 32 cards. Normally such decks are called piquet decks after the very old game Piquet, for which the number of cards was reduced from 36 to 32 around 1700.
 * "Hoyle's book of rules" is not really a specific book but a family of books form different authors and publishers, loosely held together by the fact that they all use the name "Hoyle" for marketing reasons. The best source for information on playing cards is probably Chapters 3 and 4 of Parlett's Oxford Guide to Card Games. Most (not all) information on the web is wrong or useless. Hans Adler 11:24, 6 June 2011 (UTC)
 * In reference to the above statement by Owen214 "because America introduced the Joker in order to play Bridge I think it was", the joker is not used and has never been used in bridge. Newwhist (talk) 15:08, 30 July 2012 (UTC)
 * In reference to the above statement by Newwhist, as well as the slightly more above statement by Owen214 re: the origins of the Joker, I'm guessing that the game they were thinking of was Euchre eldamorie (talk) 20:15, 30 July 2012 (UTC)
 * That's right, thanks Eldamorie. Owen214 (talk) 08:56, 25 November 2012 (UTC)

Image caption dubious
Currently there is a picture of some cards, captioned, "Medieval gambling cards, c.1377." The image shows hearts, clubs, diamonds and spades, so these cards must be from later than 1480. Ordinary Person (talk) 08:03, 14 January 2013 (UTC)

Capitalization of the word pack is dubious
Capitalization of the word "pack" in the article varies. The word generally should not be capitalized since it's not a proper noun. I won't change the article because I'm not certain, but it seems the word is incorrectly capitalized in several places in the article. Evonj (talk) 13:52, 12 June 2014 (UTC)
 * I agree with you, especially as there doesn't seem to be any consistency to when it's capitalised and when it's not. I'll attack it now but am open to reasons I could have missed as to why they're there. JaeDyWolf ~ Baka-San (talk) 14:28, 12 June 2014 (UTC)

Playing card money
I wanted to see if it would be appropriate to insert this image (and some form of the caption) in this article. Thanks-Godot13 (talk) 03:39, 28 August 2014 (UTC)

Left handed cards ?
Surprised there's no mention that the standard design of cards with 2 sets of pips are designed for a right handed player. If the cards are fanned by a naturally left handed person, then the pips are all obscured.

https://www.amazon.co.uk/Bicycle-Lefty-Deck-Playing-Handed/dp/B0030B6W7Q

This doesn't happen with cards which have a 4-pip design (e.g. Waddingtons in the UK).
 * I wrote a paragraph about 4-pip design (also in the Bias_against_left-handed_people article). Please feel invited to improve the wording and/or the links. --Cheater no1 (talk) 14:36, 9 October 2018 (UTC)

I recognize that left-handed individuals might find it helpful to know about cards marketed toward left-handed people, however, it is not necessarily proven that a design with indices on the top-left corner are any actual bias towards holding cards a particular way. Given that, the two citations about supposed “left-handed” cards existing are two links to buy “left-handed” cards. That feels wrong to me, the citation links should be articles about the subject, not links that effectively promote these cards. Louie Mantia (talk) 21:14, 30 August 2021 (UTC)

A miniature in a 14th-century manuscript
This is the earliest known depiction of card play, a miniature in a 14th-century manuscript of Meliadus or Guiron le Courtois (part of the romance also known as Palamedes; also known as Le Roman du Roy Meliadus de Lennoys), by Hélie de Boron. — Preceding unsigned comment added by Robertolyra (talk • contribs) 00:39, 26 November 2017 (UTC)

 * This is a wonderful find, and probably should be incorporated into the article, but -- quickly glancing at the summary from the British Museum -- I just wish to note that we must be cautious about making too-specific statements about the dating. This is because, while the description clearly dates the ms to "between 1352 and 1362", it also specifically calls out this very illustration as "added later". It's a little unclear whether this means "later than the text... whenever that was", or "later than 1362", but to me the context suggests the latter. I trust that someone willing to dig for fuller documentation can shed better light on this. But because 1362 appears to be right around the time that playing cards made their very first entrance into Europe, dating an important piece of evidence like this to "before 1363" or "sometime after 1362" makes a very big factual difference. Cheers. Phil wink (talk) 18:11, 2 February 2020 (UTC)

History
In the Spanish Wikipedia version of this article it is mentioned that there was a ban of playing cards in Barcelona in 1310, however in the version in English no reference to this history is made whatsoever... The section on history might need some reviewing then in the English wikipedia — Preceding unsigned comment added by 2a02:1811:d10:8300:e946:f152:aef4:9fe7 (talk • contribs) 19:24, 24 August 2021 (UTC)

 * I am reviewing the source of the quote itself.
 * The source quoted in Wikipedia in several languages has a mistake, as that page has no text!!!
 * I don't know the origin of that mistaken source, or if some other book of that author may have be the real source for that.
 * Anyway, someone somewhere would have quoted that same ban, and I cannot find anything like that. Still checking that. Looong work. Freiburger (talk) 20:35, 11 December 2022 (UTC)

The most common deck?
"The most common type of playing card is that found in the French-suite" Shouldn't the chinese suite be the most common? — Preceding unsigned comment added by 179.26.154.6 (talk) 04:02, 9 May 2022 (UTC)

History in China
Qiushufang, pretty strong research since 2020 is putting into doubt Needham's and others' supposed origin of playing cards as Yezi xi. Considering the important of the first paragraph in a Wikipedia section on the history of a thing, and considering the strength of this new evidence compared to Needham's well-known quantity over quality leading to frequent errors, I think it's appropriate to place the qualification succinctly in the first paragraph, not below as you have suggested. I still leave the reference to yezi xi basically intact as the dominant theory, but it should be prominently stated that this is recently in dispute. Hence the edits and deeper references, so as to allow future others to make further inquiry. More is needed on this: a good start would be to read Andrew Lo's paper carefully. Zelchenko (talk) 01:41, 18 January 2023 (UTC)

 * I did not delete your additions. Assuming good faith, perhaps you did not understand, the existence of a leaf game had not been established yet and the added material was a response to the leaf game, leaving the reader confused as to what the leaf game even is when the sentence pops up. I moved it to give it chronological coherence. Qiushufang (talk) 01:43, 18 January 2023 (UTC)

French playing card suits: bold, revert, discuss
The literal translation into English of the French suit names is not (Hearts, Diamonds, Clubs, Spades; these are merely their equivalents on English playing cards. The correct translation of the words themselves is Hearts, Tiles, Clovers and Pikes. Unfortunately we have repeated instances of well-meaning editors who fail to read what the line says: French –  and decide it must be vandalism. This has just happened again and a BRD challenge has been raised (even though I was reverting a previous editors mistake.) But this debate will recur repeatedly unless we agree a consensus position, so let's address it head on. Looking back 500 edits (over five years ago), it was causing difficulty then and will do so in five years time without a firm resolution.

By the way, the citations for this are at the main article, French-suited playing cards.

IMO, we have some obvious choices:

1 Add a line giving the English suits (Hearts, Diamonds, Clubs, Spades). English is international too but the main purpose of having this as a line is to intercept these misguided "corrections"

2 Give the actual French names cœurs, carreaux, trèfles and piques

 * 2.1 Exactly as is, no translations -or-
 * 2.2 with their literal translations (hearts, tiles, clovers, pikes) -or-
 * 2.3 with their equivalent names (Hearts, Diamonds, Clubs, Spades) -or-
 * 2.4 with both their literal translations and their equivalent names -or-

3 Ignore the names in French and

 * 3.1 Give only the literal translations (hearts, tiles, clovers, pikes) -or-
 * 3.2 Give only the equivalent names (Hearts, Diamonds, Clubs, Spades) -or-
 * 3.3 Give both their literal translations and their equivalent names

I think that's it but please extend as appropriate. --𝕁𝕄𝔽 (talk) 22:44, 25 September 2023 (UTC). Revised to insert a new 2.3 and 3.3--𝕁𝕄𝔽 (talk) 13:34, 26 September 2023 (UTC)

 * All the other lines use option 3.1: I see no reason to treat French any differently. So my !vote is for 1 and 3.1. --𝕁𝕄𝔽 (talk) 22:44, 25 September 2023 (UTC)
 * There is no such thing as "English suits". The French suit system is international; it is only called "French" because several centuries ago, French cardmakers created the symbols used. But since at least the 1650s, English sources have called them Clubs, Spades, Hearts and Diamonds. They are never literally translated, nor would that be meaningful and certainly not "correct". Accurate translation involves finding the nearest equivalent. Otherwise German Army captains would be called "headmen". Setting that aside, Wikipedia follows WP:RS and all the sources use Clubs, Spades, Hearts and Diamonds. So if you type in "Ace of Clovers" at Google Books, for example, you get nothing meaningful. The article at French-suited playing cards needs amending to give the English names first and original French names in brackets. Bermicourt (talk) 20:13, 26 September 2023 (UTC)

license: Creative Commons - Attribution Share-Alike - https://creativecommons.org/licenses/by-sa/4.0/

title: Talk:Playing card


text:
Talk:Italy

Italy is a regional state.
Italy is a regional state not an unitary state. The regions have political power of making laws concerning the subjects defined by the constitution. Art 117 Italian constitution. So the the government form Must change to regional parlamantelary Republic. Conforx (talk) 11:13, 5 April 2024 (UTC)

 * Do you have a source supporting this change? Nikkimaria (talk) 11:49, 5 April 2024 (UTC)
 * The Italian constitution. Conforx (talk) 16:49, 10 April 2024 (UTC)
 * https://www.governo.it/en/node/28 there isn't a stronger source then this one. Conforx (talk) 16:53, 10 April 2024 (UTC)
 * https://www.governo.it/it/costituzione-italiana/parte-seconda-ordinamento-della-repubblica/titolo-v-le-regionile-province-e-i#:~:text=la%20Regione%20interessata.-,Art.,comunitario%20e%20dagli%20obblighi%20internazionali the previous one does not work. Conforx (talk) 16:54, 10 April 2024 (UTC)

Extended-confirmed-protected edit request on 21 April 2024
Add Italy’s minorities to demographics section.

Source: https://minorityrights.org/country/italy/ 174.243.152.88 (talk) 17:53, 21 April 2024 (UTC)
 * Red question icon with gradient background.svg Not done: it's not clear what changes you want to be made. Please mention the specific changes in a "change X to Y" format and provide a reliable source if appropriate. M.Bitton (talk) 19:39, 21 April 2024 (UTC)

Insane amount of text please remove and add subheadings.
Janae amount fo text. 64.189.18.37 (talk) 18:10, 1 May 2024 (UTC)

 * I wouldn't agree. The amount of subheadings and their titles aren't unusual for a country article. 216.208.98.34 (talk) 17:32, 22 May 2024 (UTC)

Italy population 1 March 2024
Population change at the end of February 2024 (1 March 2024): 58.971.638; source: https://demo.istat.it/app/?i=D7B&a=2024&l=en

Please change it. EdgarsKiecis (talk) 05:47, 23 May 2024 (UTC)

Extended-confirmed-protected edit request on 12 June 2024
Please change "12 Jun 1946" to "10 Jun 1946" as the date on which the Italian Republic came into being. This was the date on which the Court of Cessation confirmed the results of the institutional referendum. RomeoJA (talk) 20:02, 12 June 2024 (UTC)
 * Red information icon with gradient background.svg Not done: please provide reliable sources that support the change you want to be made. Charliehdb (talk) 13:25, 13 June 2024 (UTC)
 * Results of the institutional referendum were announced on 10 Jun 1946; see Gazzetta Ufficiale, 20 Jun 1946:
 * https://www.gazzettaufficiale.it/do/gazzetta/downloadPdf?dataPubblicazioneGazzetta=19460620&numeroGazzetta=134&tipoSerie=FO&tipoSupplemento=GU&numeroSupplemento=0&estensione=pdf&edizione=90
 * The following day, 11 Jun 1946, was proclaimed a public holiday:
 * https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=1946-06-20&atto.codiceRedazionale=046U0002 RomeoJA (talk) 14:07, 15 June 2024 (UTC)

Extended-confirmed-protected edit request on 14 June 2024
change "Italy shares its borders with France, Switzerland, Austria, Slovenia and two enclaves: Vatican City and San Marino." to "Italy shares its borders with France, Switzerland, Austria, Slovenia, Vatican City and San Marino." or "Italy shares its borders with France, Switzerland, Austria, Slovenia and two micronations: Vatican City and San Marino." 93.46.99.50 (talk) 11:23, 14 June 2024 (UTC)
 * Red information icon with gradient background.svg Not done: 'Enclaves' is more descriptive, as Italy completely surrounds the two countries.   [[User:CanonNi ]]  (talk • contribs) 11:29, 14 June 2024 (UTC)

GDP
Greetings, everyone. The article says that Italy has the eighth-largest nominal GDP in the world, but, according to the International Monetary Fund, the county is in ninth position, which we can see here: World Economic Outlook database: April 2024. Can someone correct that information?--Agent010 (talk) 12:36, 21 June 2024 (UTC)

Administrative Divisions
Looking at the source, there is an editor comment at the Administrative Divisions section that says not to change the anchor tag. As it stands, however, the section header is " ={{Anchor ". Shouldn't this be fixed? Why shouldn't it be changed? TurkeyCookTime (talk) 18:50, 21 June 2024 (UTC)
 * I fixed it.--Bbb23 (talk) 18:57, 21 June 2024 (UTC)

Biased against Italy
A lot of this is biased against Italy and written to paint a bad image of the country.

Can we remove all the bad points? 2A0A:EF40:E4A:E101:698A:BD05:47AD:E241 (talk) 16:17, 22 June 2024 (UTC)

 * If we removed all the bad points, it would be biased towards Italy. It needs to be an appropriate balance of both the good and the bad. See WP:NPOV. Nikkimaria (talk) 05:05, 23 June 2024 (UTC)

Italy population 30 April 2024
Italy population (30 April 2024 official estimate): 58,968,501 Source: ISTAT Instituto Nazionale di Statistica: https://demo.istat.it/app/?l=en&a=2024&i=D7B

Subsequent population density: 195.7/km2

The article misleadingly states its' 2022 estimate at 58,853,482 and the population density is at 201.3/km2 EdgarsKiecis (talk) 05:21, 3 July 2024 (UTC)

Italy population 30 April 2024
Italy population (30 April 2024 official estimate): 58,968,501 Source: ISTAT Instituto Nazionale di Statistica: https://demo.istat.it/app/?l=en&a=2024&i=D7B

Subsequent population density: 195.7/km2

The article misleadingly on the right side states its' 2022 estimate at 58,853,482 and the population density is at 201.3/km2 EdgarsKiecis (talk) 06:39, 3 July 2024 (UTC)
 * ✅ Goldsztajn (talk) 08:11, 10 July 2024 (UTC)

title: Talk:Italy